KalVista Q4 2022 Earnings Report
Key Takeaways
KalVista Pharmaceuticals reported no revenue for the three months ended April 30, 2022. Research and development expenses were $19.2 million, and general and administrative expenses were $7.6 million. The net loss for the quarter was $24.1 million, or $(0.98) per share. Cash, cash equivalents, and marketable securities totaled $166.2 million as of April 30, 2022.
Enrollment is proceeding as expected for the Phase 3 KONFIDENT trial for sebetralstat, with data expected in the second half of 2023.
The Phase 2 KOMPLETE clinical trial for KVD824 also remains on track with its enrollment targets, and data from the KOMPLETE trial is expected in mid-2023.
KalVista reported promising preclinical data for its oral factor XIIa inhibitor program at the KININ2022 conference.
The Company is well-capitalized, with funding until at least early 2024, which is expected to take them beyond data from both ongoing clinical trials.